A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Inclusion Criteria: 1. Able to read and understand the informed consent document; must sign the informed consent; 2. Aged 18 to 75 years old , sex is not limited; 3. Newly Diagnosed supratentoria glioma, Must have undergone a at least a 80% resection; 4. Availability of at least 4 g tumor sample; 5. Patient must receive concurrent chemoradiotherapy (temozolomide chemotherapy and radiotherapy). 6. Karnofsky functional status rating \> or equal to 70. 7. Adequate bone marrow function including the absence of lymphopenia (ANC \> 1,500/ mm3; Hemoglobin \> 10g/dL ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[AST\], alanine amino transferase \[ALT\] \<2.5 times institutional upper limit of normals \[IULNs\] ), and adequate renal function (BUN and creatinine \<1.5 times IULNs) 8. Agree to Surgical indications of Heart \& lung and without the coagulation system disease 9. Except for surgery and radiotherapy and chemotherapy before vaccine treatment, no other cancer treatment is received. Exclusion Criteria: 1. Inability to comply with study-related procedures 2. Unavailability of at least 6 doses of vaccine 3. Severe allergies 4. Unstable or severe intercurrent medical conditions 5. Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection. 6. patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids. 7. any other clinical trials within 30 days pre-vaccination. 8. Female patients who are pregnant or breastfeeding 9. Carmustine extended release implant surgery within 6 months 10. Steroidal drugs are currently being used systemically.